Cargando…

Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics

Biomarkers can contribute to clinical cancer therapeutics at multiple points along the patient’s diagnostic and treatment course. Diagnostic biomarkers can screen or classify patients, while prognostic biomarkers predict their survival. Biomarkers can also predict treatment efficacy or toxicity and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Louie, Anna D., Huntington, Kelsey, Carlsen, Lindsey, Zhou, Lanlan, El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560682/ https://www.ncbi.nlm.nih.gov/pubmed/34737704 http://dx.doi.org/10.3389/fphar.2021.747194

Ejemplares similares

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
por: Carlsen, Lindsey, et al.
Publicado: (2022)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs
por: Huntington, Kelsey E., et al.
Publicado: (2021)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation
por: Carlsen, Lindsey, et al.
Publicado: (2022)

Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies
por: Liguori, Nicholas R., et al.
Publicado: (2021)

Targeting the Integrated Stress Response in Cancer Therapy
por: Tian, Xiaobing, et al.
Publicado: (2021)

Integrin/TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity
por: Huntington, Kelsey E., et al.
Publicado: (2022)

Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity
por: Huntington, Kelsey E., et al.
Publicado: (2022)

Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors
por: Chang, Wen-I, et al.
Publicado: (2022)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients
por: Leaf, Sofia, et al.
Publicado: (2021)

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2
por: Huntington, Kelsey E, et al.
Publicado: (2021)

Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients with COVID-19
por: Huntington, Kelsey E., et al.
Publicado: (2020)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

Therapeutic targeting of TRAIL death receptors
por: Di Cristofano, Francesca, et al.
Publicado: (2023)

Targeting Oncoproteins for Molecular Cancer Therapy
por: Allen, Joshua E., et al.
Publicado: (2016)

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
por: Kline, Christina Leah B., et al.
Publicado: (2013)

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
por: Wagner, Jessica, et al.
Publicado: (2018)

Circulating tumor cells: silent predictors of metastasis
por: Zhou, LanLan, et al.
Publicado: (2017)

The role of p53 in anti-tumor immunity and response to immunotherapy
por: Carlsen, Lindsey, et al.
Publicado: (2023)

Investing in biomedical research is important
por: El-Deiry, Wafik S
Publicado: (2013)

Welcoming Paul Dent as Assistant Editor-in-Chief of Cancer Biology & Therapy
por: El-Deiry, Wafik S
Publicado: (2013)

Are we losing the war on cancer?
por: El-Deiry, Wafik S
Publicado: (2013)

Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
por: El-Deiry, Wafik S.
Publicado: (2023)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
por: Hsu, Andrew, et al.
Publicado: (2022)

Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology
por: El-Deiry, Wafik S., et al.
Publicado: (2021)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2015)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
por: Zhao, Shuai, et al.
Publicado: (2021)

ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics
por: Hou, Jun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rap09a2chnobg0cc4gjcpn008f